Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.
紫杉醇/卡铂+ Galunisertib（一种1型TGF-B受体激酶结构域的小分子抑制剂）治疗新诊断、持续性或复发性子宫或卵巢癌肉瘤患者的可行性IB试验。
期刊:Gynecologic Oncology
影响因子:4.1
doi:10.1016/j.ygyno.2025.10.021
Washington C, Dwivedi Shailendra Kumar Dhar, Gunderson-Jackson C, Walker J, Mannel R S, Holman L L, Richardson D L, Neelakantan D, Cohoon A, Ding K, Gatalica Z, Moxley K M, Landrum L M, Rowland M R, Bhattacharya R, Moore K N
